Sun Nuclear Launches Simon Cloud-Based Platform to Monitor Linear Accelerator Health and Strengthen Radiation Therapy Quality Assurance Sun Nuclear, a Mirion Medical company, has announced the global launch of Simon™, a cloud-native, vendor-agnostic command center designed to help radiation oncology…
Kairos Pharma Presents ENV-105 Clinical Progress and Positive Interim Phase 2 Results at International Cancer Research Conference Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative treatments to overcome drug resistance in cancer, has announced that Neil Bhowmick,…
Latus Bio Presents New Preclinical Gene Therapy Data for CNS and Kidney-Targeting AAV Capsids at ESGCT 2026 Latus Bio, Inc., a biotechnology company focused on engineering and developing advanced gene therapies at scale, has announced new preclinical findings demonstrating the…
Parse Biosciences and Nomic Bio Partner to Develop Cascade, a 100 Million-Cell Dataset for AI-Driven Immune Research Parse Biosciences, a leading provider of scalable and accessible single-cell sequencing solutions and a QIAGEN company, has partnered with Nomic Bio, a leader…
Genmab Reports Positive Phase 3 LiGeR-HN1 Results for Petosemtamab Plus Pembrolizumab in Head and Neck Cancer Genmab A/S, a biotechnology company focused on developing innovative antibody-based medicines for serious diseases, has announced positive topline results from the global Phase 3…
Strand Therapeutics Doses First Patients in Phase 1 Trial of STX-003, a Programmable mRNA Therapy for Solid Tumors Strand Therapeutics, a clinical-stage biotechnology company developing programmable messenger RNA (mRNA) medicines, has announced that the first patients have been dosed in…
Monebo Technologies and Innolitics Secure FDA 510(k) Clearance for Kinetic ECG Analysis Software Library Monebo Technologies, Inc. and Innolitics have announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Kinetic Software Library, an electrocardiogram…
Merck’s Sacituzumab Tirumotecan Cuts Risk of Death by 32% in Advanced Endometrial Cancer in Phase 3 TroFuse-005 Trial Merck, known as MSD outside the United States and Canada, has announced positive results from the pivotal Phase 3 TroFuse-005 clinical trial…
Dong-A ST Presents Preclinical Findings Supporting Topical Icotrokinra Development for Psoriasis Dong-A ST Co., Ltd., a South Korean pharmaceutical company led by President and CEO Jae-hoon Jeong, has presented preclinical research findings demonstrating the potential of a topical formulation of…
Bristol Myers Squibb Reports Early Safety and Efficacy Results for Investigational CAR T-Cell Therapy Zola-Cel in Multiple Sclerosis Bristol Myers Squibb has announced interim safety and efficacy findings from the multiple sclerosis (MS) cohorts of the Phase 1 Breakfree-2 clinical…
LivaNova Reports 36-Month CORE-VNS Study Results Showing Sustained Seizure Reduction and Improved Quality of Life in Drug-Resistant Epilepsy LivaNova PLC, a medical technology company specializing in therapies for neurological and cardiac conditions, has announced the publication of the complete 36-month…
Gilead Sciences to Acquire PepStar’s Oral IL-23R Inhibitor Program for $1.275 Billion Gilead Sciences, Inc. has entered into a definitive agreement to acquire an oral interleukin-23 receptor (IL-23R) inhibitor program, including its lead investigational candidate HCXT-2001, from PepStar Therapeutics Limited,…